Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05712161
Other study ID # SP0028
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date August 7, 2023
Est. completion date December 2033

Study information

Verified date January 2024
Source Anteris Technologies Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To evaluate the safety and feasibility of DurAVR™ THV System in the treatment of subjects with symptomatic severe native aortic stenosis.


Description:

The primary objective is to assess the acute and long-term safety and feasibility of the DurAVR™ device in adult subjects with symptomatic, severe native aortic stenosis eligible for the transcatheter aortic valve replacement as assessed by the Heart Team at the enrolling institutions. This is a prospective, non-randomized, single-arm, multi-center Study. Subjects will be consented for follow-up to 10 years.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 15
Est. completion date December 2033
Est. primary completion date December 29, 2023
Accepts healthy volunteers No
Gender All
Age group 65 Years and older
Eligibility Inclusion Criteria: - Subjects are eligible for entry in this study if ALL the following conditions are met: 1. Symptomatic, severe native aortic stenosis in subjects 65 years or older 2. Requires aortic valve replacement and is indicated for TAVR as determined by the Heart Team (composed of an experienced interventional cardiologist and an experienced cardiac surgeon) 3. Eligible for transfemoral delivery of the DurAVR™ THV 4. Anatomy appropriate to accommodate safe placement of DurAVR™ THV (Preprocedural measurements by TTE and CT required: aortic annulus diameter 21-23 mm by CT) 5. Understands the study requirements and the treatment procedures and provides written informed consent 6. Subject agrees to complete all required scheduled follow-up visits. Exclusion Criteria: - Subjects are eligible for entry in this study if NONE of the following conditions are met: Anatomical 1. Anatomy precluding safe placement of DurAVR™ THV 2. Pre-existing prosthetic heart valve in any position 3. Unicuspid or bicuspid aortic valve 4. Severe aortic regurgitation 5. Severe mitral or severe tricuspid regurgitation requiring intervention. 6. Moderate to severe mitral stenosis. 7. Hypertrophic obstructive cardiomyopathy 8. Echocardiographic evidence of intracardiac mass, thrombus or vegetation requiring treatment. 9. Severe basal septal hypertrophy with outflow gradient Clinical 10. Evidence of an acute myocardial infarction = 30 days before the intended treatment. 11. Determined inoperable/ineligible for surgery by the Heart Team 12. Any percutaneous coronary or peripheral interventional procedure performed within 30 days prior to the index procedure 13. Blood dyscrasias as defined: leukopenia (WBC < 1000 mm3), thrombocytopenia (platelet count < 50,000 cells/mm3), history of bleeding diathesis or coagulopathy, or hypercoagulable states 14. Untreated clinically significant Coronary Artery Disease (CAD) requiring revascularization 15. Cardiogenic shock manifested by low cardiac output, vasopressor dependence, or mechanical hemodynamic support 16. Need for emergency surgery for any reason 17. Ventricular dysfunction with left ventricular ejection fraction (LVEF) < 30% as measured by resting echocardiogram 18. Recent (within 6 months) cerebrovascular accident (CVA) or transient ischemic attack (TIA). 19. Symptomatic carotid or vertebral artery disease 20. End stage renal disease requiring chronic dialysis or creatinine clearance < 20 cc/min. 21. GI bleeding within the past 3 months 22. A known hypersensitivity or contraindication to any of the following which cannot be adequately pre-medicated: aspirin, heparin, nitinol (titanium or nickel), ticlopidine and clopidogrel, contrast media 23. Ongoing sepsis, including active endocarditis (Duke Criteria) [49] 24. Subject refuses a blood transfusion 25. Life expectancy < 12 months due to associated non-cardiac co-morbid conditions 26. Other medical, social, or psychological conditions that in the opinion of an Investigator precludes the subject from appropriate consent 27. Severe dementia (resulting in either inability to provide informed consent for the trial/procedure, prevents independent lifestyle outside of a chronic care facility, or will fundamentally complicate rehabilitation from the procedure or compliance with follow-up visits) 28. Currently participating in an investigational drug or another investigational device trial 29. Subject is contraindicated for MDCT or MRI Scans. 30. Subject belongs to a vulnerable population (Vulnerable subject populations are defined as individuals with mental disability, persons in nursing homes, children, impoverished persons, homeless persons, nomads, refugees, and those permanently incapable of giving informed consent. Vulnerable populations also may include members of a group with a hierarchical structure such as university students, subordinate hospital and laboratory personnel, employees of the Sponsor, members of the armed forces, and persons kept in detention).

Study Design


Intervention

Device:
DurAVRTM THV System
The DurAVR™ Transcatheter Heart Valve (THV) is a balloon expandable transcatheter aortic valve

Locations

Country Name City State
United States University of Michigan Ann Arbor Michigan
United States Montefiore Medical Center Bronx New York
United States Cleveland Clinic Foundation Cleveland Ohio
United States Columbia University Medical Center/NYPH New York New York
United States Tucson Medical Center Tucson Arizona

Sponsors (1)

Lead Sponsor Collaborator
Anteris Technologies Ltd.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Hospitalization (or re-hospitalization) Hospitalization (or re-hospitalization). Any admission after the index hospitalization or study enrolment to an inpatient unit or hospital ward for =24 h, including an emergency department stay. Hospitalizations planned for pre-existing conditions are excluded unless there is worsening of the baseline condition. 1 year
Other Leaflet thickening and reduced motion Assessing causes of valve leaflet thickening and reduced leaflet motion such as leaflet thrombosis, endocarditis, leaflet deterioration, and valve frame expansion issues. 1year
Primary All-cause mortality or disabling stroke Mortality would be reported as rate of death/mortality at 30 days. Disabling stroke would be reported according to VARC-3 Guidelines 30days
Primary Technical success Freedom from mortality, successful device implant, and freedom from surgery or intervention related to the device. Immediate post procedure
Secondary All-cause mortality Mortality would be reported as rate of death/mortality at 30days. 30days
Secondary Disabling stroke Rate of disabling stroke according to VARC-3 Guidelines 30days
Secondary Major vascular, access-related, or cardiac structural complication complications according to VARC-3 Guidelines 30days
Secondary VARC-3 Type 2-4 bleeding Rates of Type 2, 3, and 4 bleeding according to VARC-3 guidelines 30days
Secondary Acute Kidney Injury stage 3 or 4 AKI stage 3-4 according to VARC-3 guidelines 30days
Secondary Moderate or severe aortic regurgitation aortic regurgitation according to VARC-3 guidelines 30days
Secondary New permanent pacemaker due to procedure related conduction abnormalities Rate of pacemaker interventions in subjects experiencing conduction abnormalities 30days
Secondary Surgery or intervention related to the device, including aortic valve reintervention. Device related interventions 30days
See also
  Status Clinical Trial Phase
Recruiting NCT04310046 - Optimal Timing of Transcatheter Aortic Valve Implantation and Percutaneous Coronary Intervention - The TAVI PCI Trial N/A
Completed NCT03332745 - Mechanism of Decompensation Evaluation - Aortic Stenosis
Recruiting NCT06008080 - Post-Market Clinical Follow Up Study With Navitor Valve
Recruiting NCT06055751 - Long Term Evaluation of Cardiac Arrhythmias After Transcatheter Aortic Valve Implantation -The LOCATE Registry
Active, not recruiting NCT04815785 - Safety and Efficacy of TaurusOne® Transcatheter Aortic Valve System in Patients With Severe Calcific Aortic Stenosis N/A
Terminated NCT02202434 - Safety and Efficacy Study of Lotus Valve for Transcatheter Aortic Valve Replacement N/A
Recruiting NCT03029026 - The Role of Occult Cardiac Amyloid in the Elderly With Aortic Stenosis.
Active, not recruiting NCT02903420 - A Clinical Trial of Transcatheter Aortic Valves in Dialysis Patients (Japan) N/A
Completed NCT02629328 - CardioCel Tri-leaflet Repair Study N/A
Completed NCT02306226 - Symetis ACURATE Neo™ Valve Implantation SAVI TF Registry
Completed NCT01676727 - ADVANCE Direct Aortic Study
Withdrawn NCT01648309 - Neuropsychological Testing in Patients Undergoing Transvascular Aortic Valve Implantation N/A
Completed NCT01422044 - Risk Prediction in Aortic Stenosis N/A
Withdrawn NCT00774657 - Ventricular Remodeling In Patients With Aortic Stenosis Assessed Echocardiography N/A
Terminated NCT00535899 - Speckle Tracking Imaging in Patients With Low Ejection Fraction Aortic Stenosis (SPArKLE-AS) N/A
Terminated NCT05070130 - OpSens PRIME CLASS
Completed NCT03314857 - China XT: Safety and Effectiveness of Edwards Lifesciences SAPIEN XT THV in the Chinese Population N/A
Completed NCT04157920 - Impact of Predilatation Between Self-expanding Valves N/A
Enrolling by invitation NCT06212050 - Feasibility, Safety, and Effectiveness of the ACURATE neo2 Transcatheter Heart Valve for Severe Bicuspid Aortic Stenosis
Recruiting NCT05893082 - Multicenter Feasibility Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR N/A